Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Directly Reprogramming Nerve Cells in the Brain

By BiotechDaily International staff writers
Posted on 04 Apr 2013
Image: Reprogrammed nerve cell (Photo courtesy of Malin Parmar).
Image: Reprogrammed nerve cell (Photo courtesy of Malin Parmar).
Generating new cells in the body to cure disease, the purview of cell therapy, has taken another significant step in the development toward new treatments. New Swedish research demonstrated that it is possible to reprogram other cells to become nerve cells, directly in the brain.

Two years ago, researchers in Lund University (Sweden) were the first in the world to reprogram fibroblasts to dopamine-producing nerve cells, without going through the stem cell stage. The scientists are now going further and shown that it is possible to reprogram both skin cells and support cells directly to nerve cells, in place in the brain.

“The findings are the first important evidence that it is possible to reprogram other cells to become nerve cells inside the brain,” said Dr. Malin Parmar, research group leader and reader in neurobiology at Lund.

The researchers employed genes designed to be switched on or off using a drug. The genes were inserted into two types of human cells, glia cells and fibroblasts, support cells that are naturally present in the brain. Once the researchers had transplanted the cells into the brains of rats, the genes were triggered using a drug in the animals’ drinking water. The cells then began their conversion into nerve cells.

In other research with lab mice, where similar genes were injected into the mice’s brains, the investigators also were able to reprogram the mice’s own glia cells to become nerve cells. “The research findings have the potential to open the way for alternatives to cell transplants in the future, which would remove previous obstacles to research, such as the difficulty of getting the brain to accept foreign cells, and the risk of tumor development,” said Dr. Parmar.

The new technique of direct reprogramming in the brain could create new ways to more successfully replace dying brain cells in disorders such as Parkinson’s disease. “We are now developing the technique so that it can be used to create new nerve cells that replace the function of damaged cells. Being able to carry out the reprogramming in vivo makes it possible to imagine a future in which we form new cells directly in the human brain, without taking a detour via cell cultures and transplants,” concluded Dr. Parmar.

The study’s findings were published March 26, 2012, in the journal Proceedings of the National Academy of Science of the United States of America (PNAS).

Related Links:

Lund University



view channel
Image: A new catalyst that improved the sensitivity of the standard PSA ELISA test by about 110-fold was made of palladium nanocubes coated with iridium (Photo courtesy of Dr. Xiaohu Xia, Michigan Technological University).

Peroxidase Mimic Outperforms Natural Horseradish Peroxidase in ELISA Test

A test-of-concept study demonstrated that a synthetic catalyst that mimics the action of horseradish peroxidase (HRP) could increase the sensitivity of a colorimetric enzyme-linked immunosorbent assay... Read more

Drug Discovery

view channel
Image: Endoscopic image of a bowel section known as the sigmoid colon afflicted with ulcerative colitis. The internal surface of the colon is blotchy and broken in places (Photo courtesy of Wikimedia Commons).

Orally Delivered Curcumin-Loaded Microparticles Effectively Treat Mouse Model of Ulcerative Colitis

Microparticles (MPs) loaded with the efficient anti-inflammatory agent curcumin were found to effectively treat a mouse model of ulcerative colitis. Ulcerative colitis is a chronic relapsing disease... Read more


view channel

Biopharmaceutical Partners Seek Alternatives to Glucocorticoid Steroid Drugs

Collaboration between American and Japanese biopharmaceutical companies is expected to lead to the development of a new class of small molecule drugs for treatment of hematological and inflammatory diseases. Gencia LLC (Charlottesville, VA, USA) and Takeda Pharmaceutical Company Ltd. (Osaka, Japan) announced the formation... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.